Therapeutics News and Research

RSS

New data on EHT 0202 for treatment of patients with AD presented at Geneva/Springfield Symposium

ExonHit Therapeutics announced today that promising new data on EHT 0202, its lead candidate in Alzheimer's disease, were presented at the 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy from March 24th to March 27th in Geneva, Switzerland.

29 Mar 2010

Maryland Technology Enterprise Institute director receives President's Award

Martha Connolly, director of the Maryland Technology Enterprise Institute Maryland Industrial Partnerships program at the University of Maryland, was given the President's Award at the Greater Baltimore Committee's fifth annual Bioscience Awards ceremony, university officials announce today.

27 Mar 2010

Evaluating potential of Ampligen and TLR3 agonists as cancer immunotherapeutics

Hemispherx Biopharma, Inc., announced today the publication of an editorial entitled "TLR3 agonists as immunotherapeutic agents," published in the March 15, 2010 edition of Immunotherapy (2010) 2(2), 137-140, co-authored by Jonathan S. Berek, MD, Chairman, Stanford University School of Medicine Department of Obstetrics and Gynecology, and Christopher F. Nicodemus, MD, Chairman and Chief Scientific Officer, Advanced Immune Therapeutics, Inc., and HEB Consultant.

26 Mar 2010

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that Pamela Pavco, Ph.D., Vice President of Pharmaceutical Development, will be presenting at the 3rd International Scar Club Meeting in Montpellier, France on March 26, 2010.

26 Mar 2010

Two separate articles describing preclinical data of ACE-041 published

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrating that treatment with ACE-041, an inhibitor of signaling through the activin receptor-like kinase 1 receptor, slows tumor growth and progression by inhibiting angiogenesis.

26 Mar 2010

NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy

Two key, independent proof-of-concept studies conducted for NellOne Therapeutics, Inc. demonstrate the potential efficacy of the company’s lead therapeutic candidate for both skeletal muscle wound healing and myocardial infarction.

26 Mar 2010

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, providing information on rebound viral genetic diversity in HIV patients treated with the personalized immunotherapy following antiretroviral therapy (ART) interruption. The data were discussed in a poster session at the Keystone Symposia Global Health Series HIV Vaccines meeting, held March 21-26, 2010 in Banff, Canada.

26 Mar 2010

Traversa Therapeutics, sanofi-aventis sign agreement for development of PTD-DRBD RNAi delivery technology

Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa’s RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.

26 Mar 2010

Eli Lilly supports SNM's initiative to advance innovative therapies

SNM is pleased to announce that biopharmaceutical company, Eli Lilly and Company, has joined SNM's Clinical Trials Network-making it the third major company to formally support this initiative to facilitate the development of promising therapeutic medicines.

26 Mar 2010

RXi Pharmaceuticals obtains commitments to purchase 2.7M shares of common stock at $6.00 per share

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, announced today that it has obtained commitments from several investors to purchase 2.7 million shares of its common stock at $6.00 per share and warrants to purchase 540,000 shares of its common stock for gross proceeds of $16.2 million.

26 Mar 2010

SMA Foundation completes biomarker study for Spinal Muscular Atrophy

The Spinal Muscular Atrophy (SMA) Foundation, a nonprofit organization dedicated to accelerating the development of a treatment for SMA, is pleased to announce the completion of a pilot study to identify Biomarkers for Spinal Muscular Atrophy (BforSMA) and the discovery of over 400 candidate biomarkers.

26 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent

Techulon Inc., a life sciences company, has signed worldwide exclusive license agreements with the University of Cincinnati to manufacture and sell novel transfection reagents used for research and therapeutic delivery of nucleic acids.

25 Mar 2010

Innovation holds the key for solving healthcare's dilemmas, says Eli Lilly

In an address to the American Chamber of Commerce in Germany today, John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company, said that innovation holds the key to solving one of healthcare's thorniest dilemmas: how to improve quality and access while controlling costs.

25 Mar 2010

Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference

ImmunoCellular Therapeutics announced today that Manish Singh, Ph.D., President and CEO, will be presenting at the Cancer Stem Cells Conference, a leading industry event, on Wednesday, March 24th at 2:00 p.m. eastern time.

25 Mar 2010

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

Pernix Therapeutics Holdings acquires oral third-generation cephalosporin, CEDAX

Pernix Therapeutics Holdings, Inc. today announced the acquisition of the antibiotic CEDAX® (ceftibuten) from Shionogi Pharma, Inc.

25 Mar 2010

Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study

Pain Therapeutics, Inc. today announced encouraging clinical data with PTI-188, an early-stage drug for metastatic melanoma. Metastatic melanoma is a lethal form of skin cancer in which patients typically have a median survival time of 9 months.

24 Mar 2010

Pluristem Therapeutics receives European Patent on core 3D cell expansion technology

Pluristem Therapeutics Inc. today announced that it has been granted a European Patent on its core 3D cell expansion technology. The granting of the European patent follows the issuance of several corresponding US patents as well as corresponding patents in ten additional jurisdictions.

23 Mar 2010

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has earned a $20 million technology transfer payment from Takeda Pharmaceutical Company Limited as part of the strategic alliance the companies formed in May 2008.

23 Mar 2010

Therapeutics News and Research

New data on EHT 0202 for treatment of patients with AD presented at Geneva/Springfield Symposium

Maryland Technology Enterprise Institute director receives President's Award

Evaluating potential of Ampligen and TLR3 agonists as cancer immunotherapeutics

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

Two separate articles describing preclinical data of ACE-041 published

NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Traversa Therapeutics, sanofi-aventis sign agreement for development of PTD-DRBD RNAi delivery technology

Eli Lilly supports SNM's initiative to advance innovative therapies

RXi Pharmaceuticals obtains commitments to purchase 2.7M shares of common stock at $6.00 per share

SMA Foundation completes biomarker study for Spinal Muscular Atrophy

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent

Innovation holds the key for solving healthcare's dilemmas, says Eli Lilly

Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference

Evotec AG reports financial results and corporate updates for 2009

Pernix Therapeutics Holdings acquires oral third-generation cephalosporin, CEDAX

Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study

Pluristem Therapeutics receives European Patent on core 3D cell expansion technology

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News